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A B S T R A C T
Novel polyelectrolyte complex nanoparticles (AAP/LCS NPs) were prepared in this study and
these were produced by mixing negatively charged auricularia auricular polysaccharide (AAP)
with positively charged low molecular weight chitosan (LCS) in an aqueous medium. The
AAP was extracted and purified from auricularia auricular, and then characterized by
micrOTOF-Q mass spectrometry, UV/Vis spectrophotometry, moisture analyzer and SEM.The
yield, moisture, and total sugar content of the AAP were 4.5%, 6.2% and 90.12% (w/w), re-
spectively. The AAP sample was water-soluble and exhibited white flocculence. The
characteristics of AAP/LCS NPs, such as the particle size, zeta potential, morphology, FT-IR
spectra, DSC were investigated. The results obtained revealed that the AAP/LCS NPs had a
spherical shape with a diameter of 223 nm and a smooth surface, and the results of the
FT-IR spectra and DSC investigations indicated that there was an electrostatic interaction
between the two polyelectrolyte polymers. Bovine serum albumin (BSA, pI = 4.8) and bovine
hemoglobin (BHb, pI = 6.8) were used as model drugs to investigate the loading and release
features of the AAP/LCS NPs.The results obtained showed that the AAP/LCS NPs had a higher
entrapment efficiency (92.6%) for BHb than for BSA (81.5%). The cumulative release of BSA
and BHb from AAP/LCS NPs after 24 h in vitro was 95.4% and 91.9%, respectively. The in
vitro release demonstrated that AAP/LCS NPs provided a sustained release matrix suitable
for the delivery of protein drugs. These studies demonstrate that AAP/LCS NPs have a very
promising potential as a delivery system for protein drugs.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Currently, over 160 therapeutic protein drugs have been li-
censed, and even more protein drugs will be approved by
regulatory agencies in the next few years [1]. The physico-
chemical and biological properties of protein drugs are unlike
those of conventional ones, particularly with regard to their
molecular weight, solubility, physico-chemical stability, bio-
logical half-life, conformational stability, oral bioavailability, dose
requirements, and administration [2]. Moreover, oral protein
drugs usually exhibit a low level of bioavailability. The major
challenges to be overcome involve poor protein absorption and
internalization through the gastrointestinal epithelium, as well
as the rapid hydrolysis and degradation by gastrointestinal fluids
[3,4]. Hence, the design and manufacturing of delivery systems
for protein is attracting much attention.
In order to overcome the above obstacles and increase the
gastrointestinal uptake, some nanoparticles made from natural
biodegradable polymers have been exploited and applied to
protein drugs [5,6]. However, biodegradable polymer
nanoparticles made from polyglycolic acid and polylactide and
their copolymers are usually obtained by using organic sol-
vents, high temperatures and sheer forces and are easily
inactivated by physical and chemical denaturation. Further-
more, after the formulation has been administered, changes
in the microenvironment can lead to polymer degradation
which can dramatically affect the tertiary structure of the
protein [7,8].
Entrapping protein drugs within polysaccharide
nanoparticles is an effective way of protecting them from deg-
radation in the gastrointestinal fluids, delivering protein drugs
to the target sites for release and increasing their perme-
ation across the gastrointestinal epithelium [9–11]. Natural
polysaccharides have many promising properties, including
excellent biodegradability, high biocompatibility, low toxicity,
good safety, abundant availability, and their cost of produc-
tion is low [12].Moreover,most polysaccharides have hydrophilic
groups, such as hydroxyl, carboxyl, and amino groups, which
may form non-covalent bonds with biological tissues like the
intestinal mucosa to facilitate the absorption of protein drugs
[13,14].
Consequently, many references [5,15] have described how
polyelectrolyte complex (PEC) nanoparticles are formed spon-
taneously by mixing oppositely charged polyelectrolytes in
aqueous media without any chemical covalent cross-linker
[16,17], and such PEC nanoparticles have bright application pros-
pects for protein drugs. The major interactions between the
two polyelectrolyte polymers are electrostatic, formation of hy-
drogen and hydrophobic bonds, as well as dipole–dipole
association [18].
Auricularia auricular polysaccharide (AAP) is abundant in
auricularia auricular, and is a significant bioactive substance,
with broad physiological activity and which is attracting much
attention because of its potential medical applications [19].
However, AAP as a novel natural polysaccharide has not been
studied in any detail with regard to its use as a drug carrier.
Hence, in this study, we used AAP as a negatively charged poly-
electrolyte to form PEC with Chitosan (a cationic polyelectrolyte
in acidic medium).
Based on the reasonsmentioned above, the goal of this paper
is to manufacture AAP/LCS NPs, composed of positively charged
low molecular weight chitosan (LCS) and negatively charged
AAP. Two model protein drugs with different pI values, BSA
(pI = 4.8) and BHb (pI = 6.8), were used to investigate the protein
loading capacity and release of AAP/LCS NPs. The physico-
chemical characteristics of the prepared nanoparticles were
characterized by investigation of Fourier transform infrared
spectra (FT-IR), particle size, zeta potential, differential scan-
ning calorimetry (DSC) and transmission electron microscopy
(TEM). The results obtained indicated that novel AAP/LCS NPs
had a very promising potential as a delivery system for protein
drugs.
2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA) and bovine hemoglobin (BHb) were
purchased from Sigma–Aldrich (St. Louis, MO, USA). Coomassie
brilliant blue G-250 was obtained from Regent Chemicals Co.,
Ltd (Tianjin, China). Auricularia auricular was bought from a
Carrefour supermarket (Shenyang, China), and it had been
grown in Liaoning Province, China. Low molecular weight
chitosan was purchased from Golden-Shell Pharmaceutical Co.,
Ltd (Zhejiang, China), and the degree of deacetylation was 90%.
All other reagents and chemicals were of analytical grade.
2.2. Extraction and purification of AAP
The AAP was extracted and purified by a modified water ex-
traction and alcohol precipitation method [20]. For this, the
auricularia auricular was defatted by reflux, dried and the re-
sulting powder was weighed and extracted, then subjected to
precipitation and washing with ethanol, to obtain crude grey
polysaccharide by vacuum-drying. A 2% crude polysaccha-
ride solution was prepared by removing protein by the Sevag
method (chloroform: n-butanol = 4:1). The pH was adjusted to
8.0 with ammonia, and the color was removed with hydro-
gen peroxide. Then, the decolorized polysaccharide solution
was dialyzed against distilled water and purified AAP was ob-
tained by concentrating and freeze-drying the dialysate.
2.3. Characterization of AAP
2.3.1. Polysaccharide content
TheAAP content wasmeasured by phenol-sulfuric acid method
using D-glucose as a standard [21]. The percentage of AAP ex-
traction yield (%) was calculated with the formula as follow:
Yield
W
W
%( ) = ×2
1
100 (1)
WhereW2 is the polysaccharides content of extraction, and
W1 represents the dried sample weight.
The protein of the polysaccharide was detected by UV-
4802 Double Beam UV/Vis Spectrophotometer (Unico, Shanghai,
China). The moisture content of the AAP was obtained by a
moisture analyzer (Shuangquan, Shanghai, China).
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2.3.2. Molecular weight (Mw)
The molecular weight of the AAP was determined by time-of-
flight mass spectrometry (Bruker micrOTOF-Q, Ettlingen,
Germany). The LC-Q-TOF/MS instrument parameters were as
follows: electrospray ionization (ESI) detection mode, capil-
lary voltage 4.5 kV, capillary exit voltage −500 V; collision cell
RF voltage 800 Vpp; capillary temperature 180 °C; N2 was used
as the fog and auxiliary gas and the flow rate was 4 mL/min.
Argon was used as the collision gas for CID experiments, and
the collision energy was 20 eV. The analytical data were col-
lected in full scan mode from 50 m/z to 900 m/z.
2.3.3. SEM
The morphology and structural characteristics of the AAP were
examined by SEM (SSX-550, Shimadzu, Japan). Each sample was
thinly sprinkled onto a metal stub and vacuum-coated with
a thin layer of gold in an argon atmosphere.The coated samples
were examined at an acceleration voltage of 15 kV.
2.4. Preparation of AAP/LCS NPs
The AAP/LCS NPs were prepared by a modified coacervation
method [22]. Preliminary experiments indicated that the con-
centration of AAP and LCS would affect the particle size and
appearance.As a result, the concentrations of AAP and LCS were
selected as two independent variables. AAP was dissolved in
5mL deionized water, similarly, while LCS was dissolved in 5mL
acetic acid solution.The LCS solution was added slowly to the
AAP solution with magnetic stirring for half an hour at room
temperature. BSA or BHb AAP/LCS NPs were produced by the
method described above (Method A), except that different
amounts of BSA or BHb were dissolved in the LCS solution
(1.0 mg/ml) before adding the AAP solution. In an adjusted
method (Method B), nanoparticles were prepared by adding
protein to the AAP solution (2.5 mg/ml). In Method C the protein
were added to an AAP/LCS NPs suspension with magnetic stir-
ring for half an hour.
2.5. Characterization of AAP/LCS NPs
2.5.1. pH measurement
The pH value of samples was measured at 20 ± 0.1 °C in a Sar-
torius PB-10 standard pH meter with an error of 0.01 pH units.
The pH-meter was calibrated with two buffer solutions before
use.
2.5.2. FT-IR spectroscopy
Fourier transform infrared spectra (Bruker IFS55FTIR, Ettlingen,
Germany) was recorded in the KBr method to identify the func-
tional groups that might be involved in the formation of the
nanoparticles, to investigate the interaction between the –NH3+
of LCS and the –COO− of AAP.
2.5.3. DSC
The thermal properties of the samples were examined by
DSC (DSC-60, Shimadzu, Japan). The samples were scanned
at a heating speed of 5 °C/min over a temperature range of
20–300 °C with a nitrogen purge of 40 mL/min in aluminum
pans sealed hermetically, using aluminum oxide as a refer-
ence.The melting point and crystallization point corresponded
to the maximum and minimum, respectively, of the DSC
curves.
2.5.4. Particle size and zeta potential and morphology
The mean particle size, polydispersity index, and zeta poten-
tial were determined using a Zeta-sizer Nano instrument
(Malvern Instruments, UK) at room temperature. Each mea-
surement was performed in triplicate. TEM (JEM-1200EX JEOL,
Tokyo, Japan) was used to investigate the morphology of AAP/
LCS NPs. Briefly, the samples were applied to carbon-coated
copper grids, blotted, washed, negatively stained with 2% (w/
v) phosphotungstic acid, air dried, and then observed directly
by TEM.
2.6. Determination of entrapment efficiency (EE) and
loading capacity (LC)
The protein-loaded AAP/LCS NPs were separated from the sus-
pension by centrifugation at 20, 000 rpm for 30 min, 5 °C. The
supernatant of the non-loaded protein was stained by the
Coomassie Blue Method. The EE and LC of the nanoparticles
were calculated as follows:
EE
W W
W
T F
T
%( ) = − × 100 (2)
LC
W W
W
T F
N
%( ) = − × 100 (3)
Where the WT was the total weight of protein, the WF was
the weight of free protein and WN was the weight of protein-
loaded AAP/LCS NPs.
2.7. Evaluation of nanoparticles stability
The stability of the nanoparticles was investigated in a buffer
solution (pH 1.2 and 7.4, respectively) at room temperature,
which simulated the pH conditions in the GI tract. Fresh sus-
pensions of nanoparticles were diluted with buffer solution and
then the particle size of the drug-loaded nanoparticles wasmea-
sured for several hours at room temperature.
2.8. In vitro release
Protein-loaded AAP/LCS NPs release studies were carried out
by the dialysis technique. For this, 2 mL samples of suspen-
sion were placed in a pre-soaked dialysis bag (8000–12,000
molecular weight cut-off) and put in conical flask containing
50 mL buffer solution (pH 1.2 and 7.4, respectively), then shaken
at a speed of 80 rpm and incubated at 37 °C on a water-bath
thermostatic oscillator.At specific time intervals, 0.5 mL samples
were withdrawn and replaced with fresh PBS to maintain a con-
stant volume. The amount of protein in the solution was
analyzed by UV/Vis Spectrophotometry at 595 nm. All inves-
tigations were performed in triplicate.
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3. Results and discussion
3.1. Characterization of AAP
3.1.1. Physicochemical properties of AAP
Purified AAP was obtained by hot-water extraction, ethanol pre-
cipitation, removal of protein by the Sevag method, dialysis
against distilled water and lyophilized by freeze-drying. The
yield, moisture, and total sugar contents in the AAP were 4.5%,
6.2% and 90.12% (w/w), respectively.TheAAP sample was water-
soluble and exhibited a white flocculence. AAP did not exhibit
a significant absorption peak at 280 nm by UV/Vis spectro-
photometry, which indicated that the protein impurities were
reduced to a very low level [23]. This result may due to the
process of vacuum freeze-drying, because the water precipi-
tated from the polysaccharide solution during freezing of the
solution, changed the solution system and denatured the
protein molecules finally leading to its lower solubility [24].
3.1.2. Molecular weight and SEM
Mass spectrometry was used to determine themolecular weight
of AAP. The Mw of AAP ranged from 20,506.9Da to 63,923.7Da.
The surface topography and structure of a polysaccharide is
affected by the methods of extraction, purification and prepa-
ration used [25]. Fig. 1 shows the surface morphology of AAP
dried by vacuum and lyophilization. AAP obtained by freeze-
drying had continuous porous sheet shape with a loose
structure, whereas the one produced by vacuum drying had
a smooth surface and a spherical shape with tight structure.
Comparing the two AAP products, we found that the freeze-
dried AAP dissolved more easily and faster than the other one
[26].
3.2. Preparation of AAP/LCS NPs
The scheme for the preparation of AAP/LCS NPs is shown in
Fig. 2. Based on the theory of polyelectrolytes [27], we inves-
tigated the feasibility of using polyelectrolyte complexes to
prepare AAP/LCS NPs. When the two polysaccharide solu-
tions were mixed by dropping, three different phenomena were
observed: a clear solution, an opalescent suspension and an
aggregated precipitate, where the opalescent suspension was
considered to be a suspension of fine particles, in the nano-
meter range, that was the polyelectrolyte complexes
nanoparticles. Nanoparticles could be formed using AAP with
concentrations of 1.5–3.0 mg/ml and 0.5–1.5 mg/ml for LCS.
Higher concentrations (>3.0 mg/ml for AAP and >1.5 mg/ml for
LCS) led to aggregation, while lower concentrations (<1.5 mg/
ml for AAP and <0.5 mg/ml for LCS) resulted in the formation
of very few nanoparticles and, hence, the solution was clear.
The PEC process was quite gentle and involved the mixture
of two aqueous phases at room temperature. The param-
eters, which included the effects of the pH value, AAP
concentration, LCS concentration, LCS molecular weight and
protein concentration on mean particle size, polydispersity
index (PDI), zeta potential and entrapment efficiency of theAAP/
LCS NPs were investigated, and the results are listed in
Tables 1–4 and Figs. 3–7 respectively.
3.2.1. Effect of pH value
The effect of the pH on the particle size, and PDI of AAP/LCS
NPs is shown in Table 1.When the pH ranged from 3.0 to 6.0,
the AAP/LCS NPs remained relatively stable but, when the pH
increased to 7.0, most of the amine groups of LCS were hardly
protonated at all, leading to weaker electrostatic attractions
and tangling loosely and, so the particle size of the nanoparticles
Fig. 1 – SEM images of AAP dried by (A) vacuum and (B)
lyophilization.
Fig. 2 – Scheme for the preparation of AAP/LCS NPs.
Table 1 – Effects of pH value on the particle size and PDI
of AAP/LCS NPsa.
pH value Sizes (nm) PDI
3.0 310.2 ± 1.7 0.175 ± 0.01
4.0 280.5 ± 3.1 0.145 ± 0.02
5.0 231.7 ± 1.9 0.189 ± 0.02
6.0 278.3 ± 2.2 0.155 ± 0.01
7.0 508.4 ± 0.6 0.181 ± 0.02
a LCS concentration = 1.0 mg/ml,AAP concentration = 2.5 mg/ml, LCS
Mw = 25 kDa, n = 3.
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was markedly increased.The AAP/LCS NPs were pH-sensitive,
and this may be used for the development of drug delivery
systems [28].
As shown in Fig. 3, the entrapment efficiency of BHb was
higher than that of BSA at different pH values. The pI of BHb
(pI = 6.8) was marginally higher than that of BSA (pI = 4.8), so,
one of the reasons may be the ionic interaction between protein
and AAP. BHb had a higher pI than BSA, which allowed much
more positively charged BHb to be attracted and combined with
negatively charged AAP. By contrast, BSA was charged nega-
tively under the same circumstances and excluded the similarly
charged AAP.Therefore, the entrapment efficiency of BHb was
higher than that of BSA.
3.2.2. Effect of AAP concentration
Previous studies [29,30] have indicated that the concentra-
tion of polysaccharide solution was a decisive parameter in the
formation of nanoparticles by the polyelectrolyte complex
method. As shown in Table 2, the particle size of AAP/LCS NPs
increased from 187 to 346 nm as the concentration of AAP in-
creased from 1.5 to 3.0 mg/ml.When the concentration of AAP
was over 3.0 mg/ml, the AAP/LCS NPs tended to aggregate and
precipitate. For this reason, with the increased concentration
of AAP, AAP molecules entangled with more LCS molecules so
that the AAP/LCS NPs became larger and larger. The zeta po-
tential of AAP was estimated to be −55.4 mV.This showed that
the structure of AAP/LCS NPs had positive LCS chains en-
tangled with negative AAP chains. In addition, the AAP content
increase could lead to a decrease in the zeta potential of AAP/
LCS NPs. In addition, the AAP content increase could lead to
the decrease of the zeta potential of AAP/LCS NPs.
3.2.3. Effect of LCS concentration
As shown in Table 3, the particle size increased with an in-
crease in LCS concentration. For example, when the LCS
concentration increased from 0.5 to 1.5 mg/ml, the particle size
increased from 186 to 526 nm.The Zeta potential refers to the
surface charge of the nanoparticles. Interestingly, the AAP/
LCS NPs displayed a negative zeta potential of −20.9 mV.
Compared with reported chitosan nanoparticles [31,32], the zeta
potential of nanoparticles prepared with a low concentration
of chitosan were negatively charged,whereas nanoparticles pre-
pared under a high concentration of chitosan had a positive
zeta potential. However, in our experiment, it was difficult to
prepare positively charged AAP/LCS NPs, and this may be due
to the fact that LCS chains were covered by AAP chains, which
had a much higher molecular weight and a lower flexibility.
3.2.4. Effect of LCS Mw
Regarding the influence of the LCS molecular weight on the
particle size and PDI (in Table 4), it appeared that an increase
in the LCS molecular weight might contribute to a larger par-
ticle size.When the LCSmolecular weight was less than 25 kDa,
very few nanoparticles were formed, and a clear solution was
obtained.As the LCSmolecular weight increased beyond 25 kDa,
the AAP/LCS NPs particle size gradually increased. To explain
this phenomena, the formation mechanism of AAP/LCS NPs
needs to be discussed [33]. The formation of AAP/LCS NPs is
determined by the electrostatic interaction between
Fig. 3 – Effects of pH value on the entrapment efficiency of
protein-loaded AAP/LCS NPs*. *Protein
concentration = 1.0 mg/ml, LCS concentration = 1.0 mg/ml,
AAP concentration = 2.5 mg/ml, LCS Mw = 25 kDa, n = 3.
**Indicated that P < 0.05.
Table 2 – Effects of AAP concentration on the particle
size, PDI, and zeta potential of AAP/LCS NPsa.
AAP
(mg/ml)
Sizes
(nm)
PDI Zeta
potential (mV)
1.5 187.8 ± 4.8 0.144 ± 0.01 −15.9 ± 1.8
2.0 258.7 ± 3.4 0.130 ± 0.02 −17.1 ± 0.8
2.5 302.5 ± 2.9 0.092 ± 0.02 −20.5 ± 1.8
3.0 346.2 ± 5.3 0.095 ± 0.01 −27.6 ± 2.6
3.5 – – –
a LCS concentration = 1.0 mg/ml, LCS Mw = 25 kDa, n = 3.
Table 3 – Effects of LCS concentration on the particle
size, PDI, and zeta potential of AAP/LCS NPsa.
LCS
(mg/ml)
Sizes
(nm)
PDI Zeta
potential (mV)
0.5 186.3 ± 2.4 0.152 ± 0.02 −20.9 ± 1.5
1.0 258.6 ± 4.8 0.172 ± 0.01 −15.6 ± 2.7
1.5 526.4 ± 2.3 0.192 ± 0.02 −13.8 ± 2.2
2.0 – – –
a AAP concentration = 2.5 mg/ml, LCS Mw = 25 kDa, n = 3.
Table 4 – Effects of chitosan molecular weight on the
particle size, PDI of AAP/LCS NPsa.
LCS Mw (kDa) Sizes (nm) PDI
10 – –
25 213.7 ± 2.3 0.152 ± 0.02
50 261.5 ± 3.6 0.172 ± 0.03
100 329.1 ± 2.5 0.132 ± 0.02
a AAP concentration = 2.5 mg/ml, LCS concentration 1.0 mg/ml, n = 3.
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negatively charged AAP and positively charged LCS, in this
process, LCS serves as an ionic cross-linking reagent. In the
cross-linking, an appropriate molecular weight of LCS is needed
for the formation of nanoparticles.
As shown in Fig. 4, the molecular weight of LCS has a more
marked influence on the entrapment efficiency of BSA.When
the LCS molecular weight was 25 kDa, the entrapment effi-
ciency of BSA and BHb reached a maximum, 75.9% and 93.9%,
respectively. It seems that a higher molecular weight of LCS
would lead to a higher encapsulation efficiency because the
longer chain of LCSmolecules could entrapmore protein [34,35].
However, as shown in Table 4, the LCS molecular weight also
affected the size of the AAP/LCS NPs.A higher molecular weight
of LCS would lead to a reduction in the specific surface area
of AAP/LCS NPs because of the increasing of particle size.There-
fore, an appropriate LCS molecular weight is essential to obtain
a high protein encapsulation efficiency.
3.2.5. Effect of protein concentration
As shown in Fig. 5, with the BSA concentration increased, the
mean particle size also increased. In addition, the zeta poten-
tial increased at the same time, probably due to the loading
of positively charged BSA. However, as the BHb concentra-
tion increased, the particle size also gradually increased while
the zeta potential decreased rapidly for negatively charged BHb.
As the protein concentration increased to 1 mg/ml (Fig. 6), the
entrapment efficiency increased slightly. The high entrap-
ment efficiency of protein could be due to the ionic interaction
betweenAAP and protein.Too high a protein concentrationmay
lead to aggregation [36].
3.2.6. Effect of ionic strength
The nanoparticles were fabricated by the method described,
except that different amounts of NaCl were dissolved in the
LCS solution before adding the AAP solution.The effect of ionic
strength on the particle size of nanoparticles is shown in
Table 5. When a low concentration of NaCl solution (0.025,
0.05 mol/L) was added, the particle size of the nanoparticles
lower than those without NaCl solution while, at a high con-
centration of NaCl solution (0.10, 0.15 mol/l), the particle size
of the nanoparticles fell sharply. This may due to the fact that
the addition of NaCl favored the formation and growth of
nanoparticles, as indicated in a previous study [28]. However,
the addition of NaCl also weakened the electrostatic attrac-
tion between the AAP and LCS chains. Thus, at high NaCl
concentrations, the effect of the interaction between the two
chains exceeded the effect on the formation and growth of
Fig. 4 – Effects of chitosan Mw on the entrapment efficiency
of protein-loaded AAP/LCS NPs*. *Protein
concentration = 1.0 mg/ml, LCS concentration = 1.0 mg/ml,
AAP concentration = 2.5 mg/ml, n = 3. **Indicated that
P < 0.05
Fig. 5 – Effect of different amounts of protein (0, 0.1, 0.2, 0.5,
1.0 mg/ml) on the particle size and zeta potential*. *LCS
concentration = 1.0 mg/ml, AAP concentration = 2.5 mg/ml,
LCS Mw = 25 kDa, n = 3.
Fig. 6 – Effects of protein concentration on the entrapment
efficiency of protein-loaded AAP/LCS NPs*. *LCS
concentration = 1.0 mg/ml, AAP concentration = 2.5 mg/ml,
LCS Mw = 25 kDa, n = 3.
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nanoparticles. In addition, it is very likely that AAP/LCS NPs
are stable in NaCl solution.
3.3. Entrapment efficiency and loading capacity
Free protein was determined by the Coomassie blue method,
and the entrapment efficiency of BSA and BHb was 81.5% and
92.6%, and the loading capacity of BSA and BHb was 32.2% and
34.1%, respectively. It is difficult to encapsulate protein com-
pletely within nanoparticles [35], owing to the electrostatic
interaction between the nanoparticles and protein, most of the
protein must be absorbed on the surface of the nanoparticles.
Based on the results above, the entrapment efficiency could
be optimized by selecting an appropriate molecular weight of
LCS and optimal preparation conditions. At different pI of the
protein packaged, AAP had a better loading capacity for BHb,
but BSA could also have an acceptable package by adjusting
the system pH. In a word, the ionic interaction between the
negative charges of AAP and the state of the protein in the
system plays a crucial role in effectively entrapping drugs in
nanoparticles.
3.3.1. Effect of different preparation methods
Fig. 7 illustrated the effect of different preparation methods
on entrapment efficiency and loading capacity of protein-
loaded AAP/LCS NPs. In method B, protein was predissolved
in the AAP solution, with a higher entrapment efficiency and
loading capacity than that obtained by the other two prepa-
ration methods. This may due to ionic interaction and ionic
cross-linking between positively charged BSA (pI = 4.8) and nega-
tively charged AAP in solution (around pH 4.3) [36]. However,
BHb (pI = 6.8) had a positive charge under the preparation con-
ditions used (around pH 5) and, so, an ionic interaction would
have little impact on the entrapment efficiency and loading
capacity.
3.4. Characterization of AAP/LCS NPs
3.4.1. FT-IR spectra analysis
As shown in Fig. 8, for the FT-IR spectra of LCS, the charac-
teristic peak at 1659 cm−1 is attributed to protonated amino
groups. The characteristic absorption peaks appearing at
1625 cm−1 and 1421 cm−1 can be attributed to asymmetrical and
symmetrical –COO− groups of AAP. These results suggest that
some carboxylic groups of AAP become dissociated into –COO−
groups, which would be able to react with the protonated amino
groups of LCS through electrostatic interactions to form poly-
electrolyte complexes [28]. Thus, the 1659 cm−1 peak of –NH2
bending vibration becomes weak and shifts to 1645 cm−1 in the
IR spectrum of blank nanoparticles, and the peaks of –COO−
in AAP shift to 1563 cm−1 and 1407 cm−1, respectively.
3.4.2. DSC analysis
DSC is a valid method to investigate the drug crystallinity of
compounds by determining the variation in energy and tem-
perature at the phase transition [37]. Fig. 9 shows the thermal
curves of AAP, LCS and blank nanoparticles obtained by DSC.
Sharp endothermic peaks of AAP and LCS were obtained at
246 °C and 230 °C, respectively, followed by decomposition which
indicated the crystalline nature. The disappearance of the en-
dothermic peak for blank nanoparticles was an indication of
Table 5 – Effects of NaCl concentration on the particle
size, PDI of AAP/LCS NPsa.
NaCl concentration (mol/L) Sizes (nm) PDI
0 245.7 ± 0.33 0.188 ± 0.02
0.025 200.5 ± 0.27 0.125 ± 0.01
0.05 224.2 ± 3.70 0.109 ± 0.02
0.10 287.3 ± 1.25 0.185 ± 0.02
0.15 328.4 ± 1.60 0.113 ± 0.02
a LCS concentration = 1.0 mg/ml,AAP concentration = 2.5 mg/ml, LCS
Mw = 25 kDa, n = 3.
Fig. 7 – Effects of different preparation methods the on
entrapment efficiency and loading capacity of protein-
loaded AAP/LCS NPs*. *Protein concentration = 1.0 mg/ml,
LCS concentration = 1.0 mg/ml, AAP
concentration = 2.5 mg/ml, LCS Mw = 25 kDa, n = 3.
**Indicated that P < 0.05
Fig. 8 – FT-IR spectra of (A) LCS, (B) AAP and (C) blank
nanoparticles.
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the possible electrostatic association between the two polyions
[38].
3.4.3. Particle size and TEM
The size and size distribution morphology of the AAP/LCS NPs
are shown in Fig. 10 (pH 5, AAP concentration 2.5 mg/ml, LCS
concentration 1.0 mg/ml, LCS Mw 25 kDa). Clearly, the
nanoparticles were successfully prepared with a homoge-
neous size distribution and spherical morphology.The average
diameter of the nanoparticles was 223 nm and PDI was 0.175.
3.5. Stability
Fig. 11 shows that the protein-loaded AAP/LCS NPs were more
stable in pH 1.2 buffer than pH 7.4 buffer. At pH 7.4, because
most of the carboxyl groups of AAP were in the –COO− form
and the amine groups of LCS were in the –NH2 form, the elec-
trostatic attractions were weakened in the nanoparticles so that
the two chains were tangled loosely and, as a result, the size
of the nanoparticle increased in pH 7.4 buffer.The AAP/LCS NPs
revealed a pH sensitivity, and this property may be used for
the development of new drug delivery systems.
3.6. Drug release
The drug release behavior was investigated in vitro by dialy-
sis in buffer solutions (pH 1.2 and pH 7.4 respectively).As shown
in Fig. 12, at pH 1.2, the amount of both BSA and BHb re-
leased from the nanoparticles was approximately 20%, which
means that the AAP/LCS NPs can protect protein under acidic
conditions. At pH 7.4, BSA and BHb were released from the
nanoparticles in a biphasic pattern: a fast release rate in the
first 5 h followed by a slow uniform release. The initial burst
release of BSA from the nanoparticles indicated that part of
the protein was absorbed onto the surface of nanoparticles or
loosely encapsulated in nanoparticles and, then, the slow and
constant release was due to the diffusion of BSA inside the
nanoparticles while most of the BHb was tightly conjugated
and encapsulated into the nanoparticles, and then released in
a sustained fashion with decomposition of the nanoparticles.
In addition, BHb was released slower than BSA because the sta-
bility of BHb NPs in pH 7.4 buffer solution was better than that
of BSA NPs (as shown in Fig. 11). That means that the particle
size of BSA NPs increased and allowed the BSA to be released
freely from the nanoparticles. The cumulative release of BSA
and BHb from AAP/LCS NPs after 24 h was 95.4% and 91.9%,
respectively.
Fig. 9 – DSC curve of AAP, LCS and blank nanoparticles.
Fig. 10 – (A) Particle size distribution and (B) TEM of AAP/LCS NPs.
Fig. 11 – Evaluation of the size of protein-loaded AAP/LCS
NPs size at different time*. *Protein concentration = 1.0 mg/
ml, LCS concentration = 1.0 mg/ml, AAP
concentration = 2.5 mg/ml, LCS Mw = 25 kDa, n = 3.
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4. Conclusion
Regarding the novel idea for the application of AAP as a drug
carrier, the results of this study demonstrated that the poly-
saccharide extracted and purified from auricularia auricular
could be used to prepare polyelectrolyte complex nanoparticles
with positively charged LCS. A small particle size and a nega-
tive zeta potential were observed. DSC and FT-IR analyses of
the nanoparticles provided evidence of the formation of a poly-
electrolyte complex.A higher entrapment efficiency (92.6%) was
obtained for BSA-loaded AAP/LCS NPs than the BHb counter-
part (82.3%). Factors such as different methods of preparation,
protein concentration, pH and LCSmolecular weight had a huge
effect on protein loading.The in vitro release study showed that
these protein-loaded AAP/LCS NPs were able to produce sus-
tained release in PBS.All in all, the data reported demonstrated
that AAP/LCS NPs are a promising system for the delivery of
protein drugs.
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